Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (FDF Site) – FDA 483, Apr 3, 2018

An FDA inspection of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. in Nanjing, China, revealed significant deficiencies in their manufacturing processes for sterile drug products. Observations included inadequate procedures for preventing microbiological contamination, deficiencies in environmental monitoring within aseptic processing areas, and a lack of validated control procedures for manufacturing processes. Additionally, the firm failed to adequately qualify suppliers for containers and closures by not verifying test results.